Wedbush Maintains Outperform on Aquestive Therapeutics, Raises Price Target to $9
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Aquestive Therapeutics (NASDAQ:AQST) and raises the price target from $4 to $9.
March 07, 2024 | 5:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Andreas Argyrides maintains an Outperform rating on Aquestive Therapeutics and raises the price target from $4 to $9.
The increase in price target by Wedbush from $4 to $9 reflects a significant positive adjustment in the valuation of Aquestive Therapeutics. This adjustment is likely based on the analyst's confidence in the company's future performance, which could positively influence investor sentiment and potentially lead to an increase in the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100